- Home
- IOVA vs BME Comparison
IOVA vs BME Comparison
Compare IOVA & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- BME
- Stock Information
- Founded
- IOVA 2007
- BME 2005
- Country
- IOVA United States
- BME United States
- Employees
- IOVA N/A
- BME N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- BME Trusts Except Educational Religious and Charitable
- Sector
- IOVA Health Care
- BME Finance
- Exchange
- IOVA Nasdaq
- BME Nasdaq
- Market Cap
- IOVA 1.0B
- BME 462.3M
- IPO Year
- IOVA N/A
- BME N/A
- Fundamental
- Price
- IOVA $3.56
- BME $37.31
- Analyst Decision
- IOVA Strong Buy
- BME
- Analyst Count
- IOVA 9
- BME 0
- Target Price
- IOVA $18.22
- BME N/A
- AVG Volume (30 Days)
- IOVA 9.8M
- BME 34.0K
- Earning Date
- IOVA 05-08-2025
- BME 01-01-0001
- Dividend Yield
- IOVA N/A
- BME 6.26%
- EPS Growth
- IOVA N/A
- BME N/A
- EPS
- IOVA N/A
- BME 1.44
- Revenue
- IOVA $164,070,000.00
- BME N/A
- Revenue This Year
- IOVA $182.20
- BME N/A
- Revenue Next Year
- IOVA $62.10
- BME N/A
- P/E Ratio
- IOVA N/A
- BME $28.37
- Revenue Growth
- IOVA 13698.99
- BME N/A
- 52 Week Low
- IOVA $2.70
- BME $35.53
- 52 Week High
- IOVA $14.23
- BME $43.20
- Technical
- Relative Strength Index (RSI)
- IOVA 52.93
- BME 52.87
- Support Level
- IOVA $2.89
- BME $36.09
- Resistance Level
- IOVA $3.43
- BME $36.79
- Average True Range (ATR)
- IOVA 0.28
- BME 0.81
- MACD
- IOVA 0.10
- BME 0.25
- Stochastic Oscillator
- IOVA 89.13
- BME 99.04
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.